Aliso Viejo, Calif. — December 22, 2025 — Leads & Copy — RxSight, Inc., an ophthalmic medical device company, announced today that Chief Financial Officer Shelley Thunen will transition from her role. Thunen will remain with the company until either her successor is appointed or January 31, 2026. She has also agreed to serve as a consultant after the transition.
“Shelley has been a key and trusted partner throughout some of the most important years in RxSight’s development,” said Ron Kurtz, Chief Executive Officer and President of RxSight. He also noted that Thunen developed and executed on the company’s financial strategy, helped guide RxSight from a pre-commercial company to one with more than 1,100 LDDs in the field and over a quarter million procedures performed, and shaped the foundation the company relies on today.
Andy Corley, Chairman of the Board, stated that Thunen’s judgment, integrity, and dedication helped guide the company through pivotal events, including its initial public offering in 2021, and positioned RxSight for future opportunities. He also noted the Board is sincerely appreciative of her service and the lasting mark she leaves on the organization.
RxSight, Inc. focuses on providing customized vision to patients after cataract surgery. Its RxSight® Light Adjustable Lens system includes the RxSight Light Adjustable Lens® (LAL®/LAL+®), RxSight Light Delivery Device (LDD™), and accessories. It is the first commercially available intraocular lens (IOL) technology that can be adjusted after surgery.
Shelley B. Thunen
Chief Financial Officer
sthunen@rxsight.com
Oliver Moravcevic
VP, Investor Relations
omoravcevic@rxsight.com
Source: RxSight, Inc.
